Olmesartan Medoxomil /Amlodipine Sandoz (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil /Amlodipine Sandoz, is an angiotensin II receptor blocker (ARB) presented as a fixed‑dose combination tablet for oral use. It treats hypertension, often in patients who require additional blood pressure control beyond what a single agent can provide.

GNH USA supplies Olmesartan Medoxil / Amlodipine Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan Medoxil / Amlodipine is an antihypertensive agent that works on the renin‑angiotensin system and calcium‑channel pathways to lower blood pressure. - Hypertension: provides combined blockade of angiotensin II receptors and calcium‑channel mediated vasoconstriction to achieve better blood‑pressure control. - Hypertension with high cardiovascular risk: reduces systolic and diastolic pressure, contributing to lower risk of stroke and myocardial infarction. - Hypertension resistant to monotherapy: offers an additive effect when a single‑agent regimen does not reach target blood pressure.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Dizziness or light‑headedness, especially after the first dose. - Flushing: transient warmth and redness. - Fatigue: general feeling of tiredness. - Nausea: occasional upset stomach.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of face, lips, tongue or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Hepatic dysfunction: abnormal liver enzymes or hepatitis. - Renal impairment: worsening kidney function, especially in patients with pre‑existing disease. - Hyperkalemia: elevated potassium levels, potentially leading to cardiac arrhythmia.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Renal function: evaluate creatinine clearance and adjust if necessary. - Hepatic function: check liver enzymes in patients with known liver disease. - Electrolytes: monitor potassium levels, particularly when used with potassium‑sparing agents. - Pregnancy: avoid use during the second and third trimesters; discuss risks if exposure occurs. - Concomitant antihypertensives: watch for additive blood‑pressure lowering effects. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and direct sunlight.

Olmesartan Medoxil / Amlodipine may interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of hyperkalemia, renal dysfunction. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise amlodipine plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: additive hypotensive effect, monitor blood pressure and electrolytes. - NSAIDs: may blunt antihypertensive response and affect renal function. - Lithium: increased lithium levels, monitor for toxicity. - Simvastatin: amlodipine can increase simvastatin exposure; consider dose reduction.